Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829828 | 0.86 | MAPT (0.44) | ERN1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL2943970 | 0.85 | ERN1 (0.63) | ERN1MEN1KMT2AMAPT | |
| SCHEMBL30071644 | 0.85 | ERN1 (0.63) | ERN1MEN1KMT2AMAPT | |
| SCHEMBL31152504 | 0.85 | ERN1 (0.63) | ERN1MEN1KMT2AMAPT | |
| SCHEMBL30539187 | 0.82 | MEN1 (0.55) | ERN1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL3416460 | 0.82 | MEN1 (0.55) | ERN1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL12961715 | 0.81 | ERN1 (0.52) | ERN1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7638502 | 0.80 | ERN1 (0.52) | ERN1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL7633196 | 0.80 | KMT2A (0.50) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL7633195 | 0.80 | KMT2A (0.50) | MEN1KMT2AKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10330389-A | — | — | None | — | — | JP | disclosed |
| WO-2011007877-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE EPOXY COMPOUND, LIGAND USED IN THE METHOD, COMPLEX, METHOD FOR PRODUCING THE LIGAND, AND METHOD FOR PRODUCING THE COMPLEX | 日産化学工業株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010029950-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE EPOXY COMPOUND AND OPTICALLY ACTIVE SULFOXIDE COMPOUND, LIGAND AND COMPLEX FOR USE IN THE PROCESS, AND PROCESS FOR PRODUCING THE COMPLEX | 日産化学工業株式会社 (JP) | 2010-03-18 | — | — | WO | disclosed |
| US-6784302-B2 | HIGHER ENANTIOMERIC EXCESS BY USING A SPECIFIED ZIRCONIUM (SALEN) COMPLEX AS CATALYST TO CONDUCT A BAEYER-VILLIGER REACTION OF A CYCLIC KETONE; OXIDATION USING A HYDROGEN PEROXIDE OXIDIZER TO PRODUCE CYCLIC ESTERS | KYUSHU UNIVERSITY (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1352908-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20020188123-A1 | Polydentate asymmetric ligands based on binaphthyl | DEGUSSA AG (DE) | 2002-12-12 | — | — | US | disclosed |
| EP-1256570-A1 | Polydentate asymmetric ligands based on biphenyl | Degussa AG (DE) | 2002-11-13 | — | — | EP | disclosed |
| JP-H10330389-A | OPTICALLY ACTIVE CHROMIUM COMPLEX AND ASYMMETRIC EPOXIDATION REACTION | NISSAN CHEM IND LTD | 1998-12-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | CYC1, CYP11B1, CYP17A1 | ERN1 1043/4885MEN1 1001/4885KMT2A 2709/4885 |
| US-20020188123-A1 | Polydentate asymmetric ligands based on binaphthyl | MT-ND4L, DNM1L, GNE | ERN1 3196/4885MEN1 3184/4885KMT2A 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.